Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week ® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

“The excellent survival responses reported in patients with different tumor types in the Phase 2 study is very exciting, and we look forward to seeing these promising data replicate in the pivotal ...

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system's ability to ...

GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed in both administration routes. Both IT and IV were ...

Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

A joint study conducted by the University of Bonn and the DZNE has confirmed early-stage brain inflammation in mice.

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Intensity Therapeutics, Inc. , ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the ...